Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2141 to 2150 of 2591 total matches.
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
, and generics) is
generally used to treat such infections in outpatients,
but resistance to these drugs ...
The FDA has approved the new aminoglycoside
antibiotic plazomicin (Zemdri – Achaogen) for IV
treatment of adults with complicated urinary tract
infections (cUTIs). Plazomicin is active against multi-drug-
resistant Enterobacteriaceae, including strains
resistant to other aminoglycosides.
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Testosterone Replacement Products1
Drug Some Formulations Usual Adult Dosage2 Cost3
Injectable
Testosterone ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.
In Brief: Glycopyrrolate Oral Solution for Sialorrhea
The Medical Letter on Drugs and Therapeutics • Jan 10, 2011 (Issue 1355)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issues 1355)
January 10, 2011 ...
Glycopyrrolate (Robinul, and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in patients taking clozapine for schizophrenia, and in developmentally disabled children.1-3 It has now been approved by the FDA as Cuvposa (Shionogi) for use specifically in children 3-16 years old with severe chronic drooling due to a neurologic condition, such as cerebral palsy. It is being marketed as an oral solution, which will permit more precise weight-based dosing than was possible with the...
In Brief: PCV13 for Adults 65 Years and Older
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 56 ...
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), for all adults ≥65 years old.1An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo.2Adults ≥65 years old who...
In Brief: Mifepristone by Mail for Pregnancy Termination
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
.
2. Mifepristone (RU 486). Med Lett Drugs Ther 2000; 42:101.
3. Mifepristone (Mifeprex) label ...
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must be dispensed in person to the patient.
Sevoflurane for General Anesthesia
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995 (Issue 960)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Sevoflurane (Ultane - Abbott), a volatile liquid fluorocarbon anesthetic delivered as an inhaled vapor, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia. It is being marketed as a rapidly eliminated anesthetic suitable for inpatient and outpatient surgery.
Dehydroepiandrosterone (DHEA)
The Medical Letter on Drugs and Therapeutics • Oct 11, 1996 (Issue 985)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
Ipilimumab (Yervoy) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011 (Issue 1367)
OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 51
The Medical Letter®
On Drugs and Therapeutics
Volume 53 ...
The FDA has approved ipilimumab (Yervoy – Bristol-Myers Squibb), a recombinant human monoclonal antibody, for treatment of unresectable or metastatic melanoma.
In Brief: Pancreatic Enzyme Replacement Products
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
Replacement
Products for EPI1
Drug Available Strengths Cost2
Immediate-release –
Viokace 10,440 or 20,880 ...
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal FDA approval was required; in 1991, however, the FDA told all manufacturers of pancreatic enzyme replacement products that they would have to submit a new drug application by April 2010 in order to keep their products on the market.EPI is a chronic disorder characterized by a deficiency of exocrine pancreatic enzymes, which results in malabsorption, steatorrhea, and weight loss. Irreversible EPI is...
In Brief: A New Indication for Abemaciclib (Verzenio) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
indication is 150 mg taken twice daily in
combination with tamoxifen or an aromatase inhibitor.
The drug ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
abemaciclib (Verzenio – Lilly) has been approved by
the FDA for use in combination with endocrine therapy
(tamoxifen or an aromatase inhibitor) for adjuvant
treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative, node-positive, early breast
cancer at high risk of recurrence.1It was previously
approved for the same indication, but patients were
also required to have a Ki-67 score ≥20%. About
70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3 doi:10.58347/tml.2023.1673g | Show Introduction Hide Introduction